Ataxia Market Set To Witness Significant Growth By 2024-2031: Pfizer, Inc., CRISPR Therapeutics, Sanofi, Bio-Techne Ataxia market is estimated to be valued at US$ 30,880.5 million in 2024 and is ...
Buspirone, sold under the name BuSpar, is an anxiolytic drug originally conceived as an antipsychotic for treating psychosis. Ultimately, it was found ineffective as an antipsychotic and is now mostly ...